These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 37834411)

  • 1. Epigenetic Modulators as Therapeutic Agents in Cancer.
    Patnaik E; Madu C; Lu Y
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic Targets and their Inhibitors in Cancer Therapy.
    Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
    Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Priming and Development of New Combination Therapy Approaches.
    Meneceur S; Grunewald CM; Niegisch G; Hoffmann MJ
    Methods Mol Biol; 2023; 2684():259-281. PubMed ID: 37410240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.
    Ganesan A; Nolan L; Crabb SJ; Packham G
    Curr Cancer Drug Targets; 2009 Dec; 9(8):963-81. PubMed ID: 20025605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
    Zahnow CA; Topper M; Stone M; Murray-Stewart T; Li H; Baylin SB; Casero RA
    Adv Cancer Res; 2016; 130():55-111. PubMed ID: 27037751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting epigenetic DNA and histone modifications to treat kidney disease.
    Fontecha-Barriuso M; Martin-Sanchez D; Ruiz-Andres O; Poveda J; Sanchez-Niño MD; Valiño-Rivas L; Ruiz-Ortega M; Ortiz A; Sanz AB
    Nephrol Dial Transplant; 2018 Nov; 33(11):1875-1886. PubMed ID: 29534238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer.
    Gutiérrez JR; Salgado ARM; Arias MÁ; San-Juan-Vergara H; Rada WR; Gómez CMM
    Curr Med Chem; 2022; 29(9):1503-1542. PubMed ID: 34963430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone modification therapy of cancer.
    Biancotto C; Frigè G; Minucci S
    Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic modifications in prostate cancer.
    Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
    Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of novel epigenetic molecular-targeting agents].
    Sowa Y; Sakai T
    Nihon Rinsho; 2015 Aug; 73(8):1263-7. PubMed ID: 26281676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy.
    Myasoedova VA; Sukhorukov V; Grechko AV; Zhang D; Romanenko E; Orekhov V; Orekhov AN
    Curr Pharm Des; 2019; 25(6):635-641. PubMed ID: 30950345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
    Cang S; Ma Y; Liu D
    J Hematol Oncol; 2009 Jun; 2():22. PubMed ID: 19486511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
    Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
    Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic modulators as therapeutic targets in prostate cancer.
    Graça I; Pereira-Silva E; Henrique R; Packham G; Crabb SJ; Jerónimo C
    Clin Epigenetics; 2016; 8():98. PubMed ID: 27651838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy.
    Biswas S; Rao CM
    Eur J Pharmacol; 2018 Oct; 837():8-24. PubMed ID: 30125562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
    Mai A; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.